EsoCap AG today announced the issue, by the Patent and Trademark Office, of a patent in Australia under no. 2015371725, based on patent application no. 2017132866/04 (057778). The patent is directed at the smart application technology enabling effective topical treatment of several esophageal diseases.
“Continued recognition from global jurisdictions validates EsoCap technology’s novelty,” commented Isabelle Racamier, EsoCap AG CEO. “These latest acknowledgments are significant in the context of advancing EsoCap into Phase II clinical development.”
